Amedisys Inc (NASDAQ:AMED) Shares Acquired by Northwestern Mutual Investment Management Company LLC

Northwestern Mutual Investment Management Company LLC grew its holdings in Amedisys Inc (NASDAQ:AMED) by 21.6% in the 1st quarter, Holdings Channel.com reports. The fund owned 11,204 shares of the health services provider’s stock after buying an additional 1,991 shares during the period. Northwestern Mutual Investment Management Company LLC’s holdings in Amedisys were worth $2,056,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Shilanski & Associates Inc. boosted its holdings in Amedisys by 1.1% in the first quarter. Shilanski & Associates Inc. now owns 4,868 shares of the health services provider’s stock worth $893,000 after acquiring an additional 54 shares in the last quarter. Creative Planning lifted its holdings in shares of Amedisys by 2.8% during the fourth quarter. Creative Planning now owns 1,993 shares of the health services provider’s stock worth $333,000 after purchasing an additional 55 shares during the period. NEXT Financial Group Inc lifted its holdings in shares of Amedisys by 7.7% during the first quarter. NEXT Financial Group Inc now owns 969 shares of the health services provider’s stock worth $178,000 after purchasing an additional 69 shares during the period. Municipal Employees Retirement System of Michigan lifted its holdings in shares of Amedisys by 1.2% during the fourth quarter. Municipal Employees Retirement System of Michigan now owns 5,970 shares of the health services provider’s stock worth $997,000 after purchasing an additional 70 shares during the period. Finally, Thrivent Financial for Lutherans lifted its holdings in shares of Amedisys by 0.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 8,428 shares of the health services provider’s stock worth $1,407,000 after purchasing an additional 74 shares during the period. 88.75% of the stock is owned by institutional investors and hedge funds.

Amedisys stock opened at $192.01 on Friday. The stock has a market capitalization of $6.21 billion, a PE ratio of 50.00, a price-to-earnings-growth ratio of 2.98 and a beta of 0.89. Amedisys Inc has a 12 month low of $107.17 and a 12 month high of $218.44. The business has a 50 day simple moving average of $186.56 and a 200-day simple moving average of $174.52. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.48 and a quick ratio of 1.48.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, May 6th. The health services provider reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. The business had revenue of $491.70 million during the quarter, compared to analysts’ expectations of $507.45 million. Amedisys had a return on equity of 23.09% and a net margin of 6.43%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.11 earnings per share. On average, equities research analysts anticipate that Amedisys Inc will post 4.61 EPS for the current fiscal year.

A number of equities research analysts recently commented on AMED shares. Oppenheimer reaffirmed a “buy” rating and set a $215.00 target price on shares of Amedisys in a report on Monday, April 27th. Stephens lifted their target price on Amedisys from $180.00 to $200.00 and gave the stock an “equal weight” rating in a report on Friday, February 21st. Credit Suisse Group lifted their target price on Amedisys from $206.00 to $214.00 and gave the stock an “outperform” rating in a report on Friday, February 21st. BMO Capital Markets reaffirmed a “market perform” rating and set a $215.00 target price on shares of Amedisys in a report on Friday, February 21st. They noted that the move was a valuation call. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $218.00 target price on shares of Amedisys in a report on Sunday, May 10th. Six analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $191.20.

In other news, CFO Scott G. Ginn sold 9,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $175.56, for a total value of $1,580,040.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David L. Kemmerly sold 23,437 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $175.32, for a total value of $4,108,974.84. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 4,000 shares of company stock valued at $635,950 and sold 36,053 shares valued at $6,336,849. 2.90% of the stock is owned by insiders.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Further Reading: What does a hold rating mean?

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.